Medical device company, OncoSil Medical Ltd (ASX: OSL) has provided updated on its CE Marking review after a meeting with BSI Management.
- Post Market Surveillance (PMS) Plan and Post Market Clinical Follow-up (PMCF) programme were discussed in the meeting.
- Based on the discussion, OSL has decided to formally submit the OncoSilTM device application and PMS, PMCF plans for review.
- It expects to finalise commercialisation plans in an anticipation of CE mark approval in the coming months.
By 1:23 PM AEST, OSL was trading at $0.185, down by 11.9% relative to the previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.